Telisotuzumab Adizutecan
Drug timelines are a Plus or Pro feature.
10 regulatory and trial events tracked for Telisotuzumab Adizutecan, covering 2026-02-06 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]